Phil Blog

Phil Blog

How Manufacturers Can Improve Speed to Therapy: Overcoming Common Causes of Prescription Delays

The timely initiation of a prescription therapy is critical to patients' health and quality of life and can often be a matter of life and death. Yet, a 2022 report revealed that more than 8 out of 10 patients encounter frustrating delays in accessing the medications they need to manage their health. Therapy delays not only have a profound impact on individuals' well-being but also significantly burden the healthcare system

4 Commercial Practices Shaping the Future of Life Sciences

Developing a new drug is an incredibly costly, time-consuming, and high-risk venture. In the 12-15 years it takes to move a prescription therapy from discovery into the marketplace, pharmaceutical manufacturers invest an average of $2.3 billion. Given the considerable investment to make the drug available to patients, it's critical for commercial teams to develop a go-to-market model that delivers an appropriate return on investment (ROI)

Meet Molly Fields, Director of Patient Support at Phil

The next interview in our Employee Spotlight series is with Molly Fields, Director of Patient Support at Phil. We hope you enjoy learning more about Molly and her impressive experience in the health tech industry. Tell me a little bit about yourself I'm from San Diego, Carlsbad specifically, and I have 7 brothers and sisters

Setting the Stage for a Successful, Modern Hub Services Program

This blog post was written by John Yu, Vice President, Patient Experience at Phil. Getting prescribed medications – especially those that treat more complicated, chronic conditions – into the hands of patients is like navigating a maze filled with roadblocks. Consider that out of all the products launched in 2019, only 1 out of 3 patients who tried to initiate a treatment could get it filled – with over half facing a formulary restriction and others abandoning due to cost

Rigorous Data Is Key to Convince Payers, Investors in the World of Digital Therapeutics

Editor’s Note: Prescription based digital therapies (PDTs) show tremendous promise for expanding access to care and providing treatment alternatives to help individuals improve their health. These organizations are investing heavily in bringing these treatments to patients and generating clinical evidence indicative of their clinical efficacy. These organizations, though noble in their pursuits, are beholden to the same financial realities all for-profit businesses face that operate in the life sciences industry

Ready to learn more?

Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance.